Petros PharmaceuticalsPTPI -2.15% 3-Year ROIIC % is -63.16 as of Dec. 2025. Among 941 Drug Manufacturers companies, Petros Pharmaceuticals ranks worse than 87.67% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Petros Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -63.16%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Petros Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
PTPI's 3-Year ROIIC % is ranked worse than 87.67% of 941
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs PTPI: -63.16
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Petros Pharmaceuticals 3-Year ROIIC % Related Terms
Petros Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Petros Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTPI vs STEK, KOAN, GCAN: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's 3-Year ROIIC % falls into.
Petros Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -4.641 (Dec. 2025) - -15.846 (Dec. 2022) )
/
( 2.067 (Dec. 2025) - 19.807 (Dec. 2022) )
=
11.205
/
-17.74
=
-63.16%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Petros Pharmaceuticals (PTPI) has a 3-Year ROIIC % of -63.16 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Petros Pharmaceuticals and its competitors. According to the industry distribution chart, Petros Pharmaceuticals ranks #825 out of 941 companies in the Drug Manufacturers industry, placing it in the top 87.7%.
Is Petros Pharmaceuticals' 3-Year ROIIC % too high?
Petros Pharmaceuticals' current 3-Year ROIIC % is -63.16. Based on the distribution chart, Petros Pharmaceuticals ranks #825 out of 941 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Petros Pharmaceuticals' 3-Year ROIIC % compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #825 out of 941 companies for 3-Year ROIIC %. This places Petros Pharmaceuticals in the lower half of its industry. The industry median 3-Year ROIIC % is 3.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current 3-Year ROIIC % is -63.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current 3-Year ROIIC % of -63.16. The current 3-Year ROIIC % is -63.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current 3-Year ROIIC % is -63.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 